Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01336088 | ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease | PHASE2 | COMPLETED | 83 | — | — | Apr 1, 2011 | Feb 1, 2012 | Jul 16, 2012 | 25 | United States, Austria +2 |
Physical and neurological examination, heart rate and blood pressure, 12-lead ECG, hematology and biochemistry assessments, use of concomitant medications, adverse events and serious adverse events.
| Arm | Type | Description |
|---|---|---|
| ADX48621 | EXPERIMENTAL | - |
| ADX48621 Matching Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ADX48621 | DRUG | oral administration |
| Placebo | DRUG | oral administration |
Inclusion Criteria: * outpatient with idiopathic PD according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnosis Criteria (UKPDSBBCDC) * experiences moderately disabling dyskinesia (screening visit UPDRS 33 score≥2) * has an mAIMS score at baseline ≥ 7 with a score ≥ 3 in at least ...